Difficulty: Medium
Average Score: 84%
Practice
A client hospitalized for chemotherapy has a hemoglobin of 6.1 mg/dL (61 mmol/L). The client is symptomatic but refuses blood transfusions. What medication does the nurse prepare to administer?
Correct answer
A
Rationale
In this scenario, the correct medication for the client with a hemoglobin of 6.1 mg/dL who refuses blood transfusions is option A) Epoetin alfa. Epoetin alfa is a medication that stimulates red blood cell production in the bone marrow, thereby increasing hemoglobin levels. This is crucial for a symptomatic client with a low hemoglobin level as it can improve oxygen-carrying capacity and alleviate symptoms like fatigue and weakness.
Option B) Filgrastim is a medication that stimulates the production of white blood cells and is used to prevent infection in patients undergoing chemotherapy. It is not indicated for increasing hemoglobin levels.
Option C) Mesna is a uroprotective agent used to prevent hemorrhagic cystitis in patients receiving ifosfamide or cyclophosphamide chemotherapy. It is not indicated for treating low hemoglobin levels.
Option D) Dexrazoxane is a cardioprotective agent used to prevent anthracycline-induced cardiotoxicity in patients receiving doxorubicin or daunorubicin. It is not indicated for increasing hemoglobin levels.
Educationally, understanding the rationale behind using Epoetin alfa in this context highlights the importance of managing hematologic side effects of chemotherapy. It also emphasizes the role of supportive care medications in improving quality of life for oncology patients. This case underscores the need for nurses to be knowledgeable about hematologic parameters and appropriate pharmacological interventions in oncology care.
Option B) Filgrastim is a medication that stimulates the production of white blood cells and is used to prevent infection in patients undergoing chemotherapy. It is not indicated for increasing hemoglobin levels.
Option C) Mesna is a uroprotective agent used to prevent hemorrhagic cystitis in patients receiving ifosfamide or cyclophosphamide chemotherapy. It is not indicated for treating low hemoglobin levels.
Option D) Dexrazoxane is a cardioprotective agent used to prevent anthracycline-induced cardiotoxicity in patients receiving doxorubicin or daunorubicin. It is not indicated for increasing hemoglobin levels.
Educationally, understanding the rationale behind using Epoetin alfa in this context highlights the importance of managing hematologic side effects of chemotherapy. It also emphasizes the role of supportive care medications in improving quality of life for oncology patients. This case underscores the need for nurses to be knowledgeable about hematologic parameters and appropriate pharmacological interventions in oncology care.